Genaera (GENR) Receives 'Going Concern' After Auditor Review
More News related to GENR
- Genaera (GENR) Misses Q3 EPS by 3c
- Unusual 11 Mid-Day Movers 8/28: TGIC, MBI, BDSI, SEED Higher; GENR, FCEL, WSM, FPP Lower
- Genaera Corporation (GENR) Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436)
- Genaera (GENR) Receives 'Going Concern' After Auditor Review
- Genaera (GENR) CEO Buys 30K Shares
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Genaera Corporation (Nasdaq: GENR) announced that the audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 contained an unqualified audit opinion from its independent registered public accounting firm, KPMG LLP, which included a "going concern" explanatory paragraph.
This disclosure is required under NASDAQ rules and does not represent any change or amendment to the Company's 2007 financial statements or to its Annual Report on Form 10-K which was filed on March 31, 2008 with the Securities and Exchange Commission.
Genaera Corporation (Genaera) is a biopharmaceutical company committed to developing medicines to address substantial unmet medical needs in major pharmaceutical markets. [SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
